EUA
LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete Assay
FDA Emergency Use Authorization · LumiraDx UK Ltd. · Jun 30, 2023
Key facts
| Product | LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete Assay |
|---|---|
| Company | LumiraDx UK Ltd. |
| Product type | RT, Non-isothermal Nucleic Acid Amplification qSTAR, Multi-analyte, Single Target |
| Date | Jun 30, 2023 |
| FDA page | fda.gov |
At a glance
- 1–9 Authorization documents
- 1–9 EUAs for this company
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Emergency Use Authorizations
Emergency Use Authorizations allow the FDA to permit unapproved medical products, or unapproved uses of approved products, during a declared public health emergency.
Source: U.S. Food and Drug Administration (FDA), Emergency Use Authorizations · Source date: